OLMA
Olema Pharmaceuticals, Inc. Health Care Pharmaceutical Preparations Russell 3000
$7.00Close
$569.6MMarket cap
$6.41 – $35.8352-week range
Nov 9, 2026Next report
Highlights
Cautions
- Not in an uptrend 0 of 8 trend conditions
- Lagging the market RS 3 · weaker than 97% of stocks over 12 months
- Far from its high 80% below its 52-week high
- Results soon Nov 9, 2026, in 8 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
80%
1wk
up 9.2%
price change
1mo
down 19.0%
price change
12-month return
down 20%
market up 11% ·
its own down 30%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
1.2×
price / book
Earnings yield
down 34.3%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 37%
return on equity
Free cash margin
—
-$146.7M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
7.3%
$0.51 a day · 2×ATR $5.98
RS
3 / 99
vs the universe
Trend
0 / 8
trend template
Relative volume
0.6×
vs 50-day average
Up/down volume
0.72
50 sessions
Implied move
—
no option chain · report Nov 9, 2026
Trend template · 0 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 9.5% over the year, from 74m to 81m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 10, 2026
Last shock
Aug 11, 2026-13% in one session1.8× volumeon results-33% since
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Operating income | -$21.5M | -$71.5M | -$107.0M | -$105.0M | -$142.3M | -$178.7M |
| Net income | -$22.1M | -$71.1M | -$104.8M | -$96.7M | -$129.5M | -$162.5M |
| Earnings per share | -$3.15 | -$1.80 | -$2.62 | -$2.14 | -$2.20 | -$1.87 |
| Free cash flow | -$19.9M | -$52.3M | -$82.4M | -$83.7M | -$104.5M | -$146.7M |
| Cash | $338.5M | $13.8M | $23.7M | $68.5M | $139.5M | $48.3M |
| Shareholders' equity | $338.1M | $284.6M | $197.5M | $253.9M | $409.0M | $478.6M |
| Shares outstanding | 39.31m | 39.80m | 40.29m | 54.99m | 74.31m | 81.38m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 10, 2026 | Quarterly ↗ | Jun 30, 2026 | 41d |
| May 12, 2026 | Quarterly ↗ | Mar 31, 2026 | 42d |
| Mar 16, 2026 | Annual ↗ | Dec 31, 2025 | 75d |
| Nov 10, 2025 | Quarterly ↗ | Sep 30, 2025 | 41d |
| Aug 11, 2025 | Quarterly ↗ | Jun 30, 2025 | 42d |
| May 13, 2025 | Quarterly ↗ | Mar 31, 2025 | 43d |
| Mar 18, 2025 | Annual ↗ | Dec 31, 2024 | 77d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 6, 2024 | Quarterly ↗ | Jun 30, 2024 | 37d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Mar 11, 2024 | Annual ↗ | Dec 31, 2023 | 71d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 15, 2026 | Director or officer change ↗ |
| Aug 13, 2026 | Director or officer change · Regulation FD ↗ |
| Aug 10, 2026 | Results ↗ |
| Jun 23, 2026 | Shareholder vote ↗ |
| May 26, 2026 | Regulation FD · Other events ↗ |
| May 21, 2026 | Regulation FD · Other events ↗ |
| May 12, 2026 | Results ↗ |
| May 1, 2026 | Material agreement · New obligation ↗ |
| Apr 29, 2026 | Director or officer change · Regulation FD ↗ |
| Mar 16, 2026 | Results ↗ |
| Jan 30, 2026 | Director or officer change ↗ |
| Jan 12, 2026 | Results · Regulation FD ↗ |